Cargando…

Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan

BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Quest...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattori, Nobutaka, Takeda, Atsushi, Hanya, Yuki, Kitagawa, Tadayuki, Arai, Masaki, Furusawa, Yoshihiko, Mochizuki, Hideki, Nagai, Masahiro, Takahashi, Ryosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/
https://www.ncbi.nlm.nih.gov/pubmed/35077474
http://dx.doi.org/10.1371/journal.pone.0262796
_version_ 1784639712646922240
author Hattori, Nobutaka
Takeda, Atsushi
Hanya, Yuki
Kitagawa, Tadayuki
Arai, Masaki
Furusawa, Yoshihiko
Mochizuki, Hideki
Nagai, Masahiro
Takahashi, Ryosuke
author_facet Hattori, Nobutaka
Takeda, Atsushi
Hanya, Yuki
Kitagawa, Tadayuki
Arai, Masaki
Furusawa, Yoshihiko
Mochizuki, Hideki
Nagai, Masahiro
Takahashi, Ryosuke
author_sort Hattori, Nobutaka
collection PubMed
description BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738). OBJECTIVE: To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson’s disease. METHODS: A path analysis was performed to assess the direct treatment effects of rasagiline on the PDQ-39 emotional well-being domain and the effects mediated indirectly through the influence on items related to motor symptoms by a post-hoc analysis of two clinical trials in Japan. RESULTS: In the monotherapy trial, the PDQ-39 emotional well-being domain was mainly affected indirectly through items related to motor symptoms (80.7%) composed of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II (67.2%) and Part III (13.5%). In the adjunctive therapy trial, the PDQ-39 emotional well-being domain was also mainly influenced indirectly through effects on items related to motor symptoms (1 mg/day: 54.7%, 0.5 mg/day: 57.6%) composed of MDS-UPDRS Part II (1 mg/day: 35.6%, 0.5 mg/day: 40.9%), Part III (1 mg/day: 8.0%, 0.5 mg/day: 8.3%) and mean daily OFF-time (1 mg/day: 11.1%, 0.5 mg/day: 8.4%). CONCLUSIONS: The effects of rasagiline on the PDQ-39 emotional well-being domain were mediated primarily by influence on the subjective aspects of motor experiences of daily living.
format Online
Article
Text
id pubmed-8789184
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-87891842022-01-26 Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan Hattori, Nobutaka Takeda, Atsushi Hanya, Yuki Kitagawa, Tadayuki Arai, Masaki Furusawa, Yoshihiko Mochizuki, Hideki Nagai, Masahiro Takahashi, Ryosuke PLoS One Research Article BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738). OBJECTIVE: To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson’s disease. METHODS: A path analysis was performed to assess the direct treatment effects of rasagiline on the PDQ-39 emotional well-being domain and the effects mediated indirectly through the influence on items related to motor symptoms by a post-hoc analysis of two clinical trials in Japan. RESULTS: In the monotherapy trial, the PDQ-39 emotional well-being domain was mainly affected indirectly through items related to motor symptoms (80.7%) composed of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II (67.2%) and Part III (13.5%). In the adjunctive therapy trial, the PDQ-39 emotional well-being domain was also mainly influenced indirectly through effects on items related to motor symptoms (1 mg/day: 54.7%, 0.5 mg/day: 57.6%) composed of MDS-UPDRS Part II (1 mg/day: 35.6%, 0.5 mg/day: 40.9%), Part III (1 mg/day: 8.0%, 0.5 mg/day: 8.3%) and mean daily OFF-time (1 mg/day: 11.1%, 0.5 mg/day: 8.4%). CONCLUSIONS: The effects of rasagiline on the PDQ-39 emotional well-being domain were mediated primarily by influence on the subjective aspects of motor experiences of daily living. Public Library of Science 2022-01-25 /pmc/articles/PMC8789184/ /pubmed/35077474 http://dx.doi.org/10.1371/journal.pone.0262796 Text en © 2022 Hattori et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hattori, Nobutaka
Takeda, Atsushi
Hanya, Yuki
Kitagawa, Tadayuki
Arai, Masaki
Furusawa, Yoshihiko
Mochizuki, Hideki
Nagai, Masahiro
Takahashi, Ryosuke
Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
title Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
title_full Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
title_fullStr Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
title_full_unstemmed Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
title_short Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
title_sort effects of rasagiline on parkinson’s disease questionnaire (pdq-39) emotional well-being domain in patients with parkinson’s disease: a post-hoc analysis of clinical trials in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/
https://www.ncbi.nlm.nih.gov/pubmed/35077474
http://dx.doi.org/10.1371/journal.pone.0262796
work_keys_str_mv AT hattorinobutaka effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT takedaatsushi effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT hanyayuki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT kitagawatadayuki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT araimasaki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT furusawayoshihiko effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT mochizukihideki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT nagaimasahiro effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan
AT takahashiryosuke effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan